Education
About Us
Working with TipRanks
Follow Us
Advaxis Inc (DE:FAD)
:FAD
FAD Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.01 - €0.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.48M
Enterprise Value-€21.81M
Total Cash (Recent Filing)€4.88M
Total Debt (Recent Filing)$8.32M
Price to Earnings (P/E)―
Beta-1.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,633,400
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.14
Price to Sales (P/S)0.00
P/FCF Ratio-0.22
Enterprise Value/Market Cap-4.87
Enterprise Value/Revenue-15.21
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Advaxis News
PremiumCompany Announcements
Advaxis Executive Reshuffle Following Asset Sale
PremiumCompany Announcements
Advaxis Enhances Operations Through Strategic Asset Sale
PremiumCompany Announcements
Advaxis Clarifies CMO Bonus Terms Amid Asset Sale
PremiumCompany Announcements
Advaxis Asset Sale Approved by Majority Shareholder Vote
PremiumCompany Announcements
Advaxis Executes Strategic Unregistered Equity SalesOptions Prices
Currently, No data available
---
Ownership Overview
58.95%
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
FAD FAQ
What was Advaxis Inc’s price range in the past 12 months?
Advaxis Inc lowest stock price was €0.01 and its highest was €0.24 in the past 12 months.
What is Advaxis Inc’s market cap?
Advaxis Inc’s market cap is €4.48M.
When is Advaxis Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Advaxis Inc’s earnings last quarter?
Currently, no data Available
Is Advaxis Inc overvalued?
According to Wall Street analysts Advaxis Inc’s price is currently Overvalued.
Does Advaxis Inc pay dividends?
Advaxis Inc does not currently pay dividends.
What is Advaxis Inc’s EPS estimate?
Advaxis Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advaxis Inc have?
Advaxis Inc has 42,633,400 shares outstanding.
What happened to Advaxis Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Advaxis Inc?
Currently, no hedge funds are holding shares in DE:FAD
Company Description
Advaxis Inc
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Technical Analysis
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Protagenic Therapeutics
―
ZyVersa Therapeutics
―